Navigation Links
Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
Date:9/25/2008

marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) ... market segments, including the molecular diagnostics industry. BCC Research reveals in its new report ... tests, lower test costs, and a growing need for better diagnostics as part of ...
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Corporation, a company enabling a new generation of molecular ... Mo lecule A rray (SiMoA ™ ) ... measure biomarkers of inflammation from patients with Crohn,s disease. ... was possible using Quanterix,s high sensitivity digital ELISA, allowed ...
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... CBI is pleased to announce the full agenda for ... being held September 20-22, 2011 in Philadelphia, PA. The ... from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, ... Attendees have the opportunity to customize their congress experience ...
Cached Biology Technology:Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease 2NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... implant such as a new hip or pacemaker with nanosized ... the University of Gothenburg, Sweden, can now explain why: they ... the International Journal of Nanomedicine . "Activation of ... common reasons for an implant being rejected," explains Professor Hans ...
... of ageing on the immune system received a boost ... (BBSRC) announced investment in a new 3.6 million research ... from the Babraham Institute with partners from the University ... The team hopes to illuminate a fundamental but little ...
... Livermore National Laboratory Geochemist Tom Guilderson has been ... prestigious Ernest Orlando Lawrence Award, Energy Secretary Steven ... for ground-breaking radiocarbon measurements of corals, advancements in ... processes revealing past climate variability, and the explanation ...
Cached Biology News:Cobblestones fool innate immunity 2New research aims to shed light on how aging affects immunity 2New research aims to shed light on how aging affects immunity 3Geochemist Tom Guilderson wins E.O. Lawrence Award for radiocarbon work 2
FRACTALKINE [Human] (Recombinant)...
... Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps ... ... ... ...
... System with the xPONENT Software Interface ... multi-analyte assays using Upstate's Beadlyte® reagents. ... user friendly xPONENT software developed by ... templates for commercial or home-made multiplex ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Biology Products: